GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aerpio Pharmaceuticals Inc (NAS:ARPO) » Definitions » Preferred Stock

Aerpio Pharmaceuticals (Aerpio Pharmaceuticals) Preferred Stock : $0.00 Mil (As of Jun. 2021)


View and export this data going back to 2017. Start your Free Trial

What is Aerpio Pharmaceuticals Preferred Stock?

Preferred stock is a special equity security that has properties of both equity and debt. Aerpio Pharmaceuticals's preferred stock for the quarter that ended in Jun. 2021 was $0.00 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Aerpio Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2021 was $1,166.72 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Aerpio Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2021 was $0.74.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Aerpio Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Jun. 2021 was $-1.40.


Aerpio Pharmaceuticals Preferred Stock Historical Data

The historical data trend for Aerpio Pharmaceuticals's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerpio Pharmaceuticals Preferred Stock Chart

Aerpio Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Preferred Stock
Get a 7-Day Free Trial - - - - -

Aerpio Pharmaceuticals Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Aerpio Pharmaceuticals Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.


Aerpio Pharmaceuticals  (NAS:ARPO) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Aerpio Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2021 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Aerpio Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2021 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Aerpio Pharmaceuticals's Earnings per Share (Diluted) (EPS) for the three months ended in Jun. 2021 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aerpio Pharmaceuticals Preferred Stock Related Terms

Thank you for viewing the detailed overview of Aerpio Pharmaceuticals's Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Aerpio Pharmaceuticals (Aerpio Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
9987 Carver Road, Cincinnati, OH, USA, 45242
Aerpio Pharmaceuticals Inc is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The company's product razuprotafib is a small molecule Tie2 activator being developed for the topical ocular treatment of primary open-angle glaucoma. Other products under the pipeline are ARP-1536 and AKB-4924.
Executives
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Pravin Dugel director C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242
Caley Castelein director THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Anupam Dalal director 88 KEARNY STREET, SUITE 1800, SAN FRANCISCO CA 94108
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Steven Prelack director 7 WHEELWRIGHT ROAD, MEDFIELD MA 02052
Regina Marek officer: Vice President of Finance C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, SUITE 420, CINCINNATI OH 45242
Joseph H. Gardner director, officer: President C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242
Kevin G. Peters officer: See Remarks C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, C OH 45242
Muneer A Satter director, 10 percent owner C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Chau Quang Khuong director, 10 percent owner C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Michael W Rogers officer: See Remarks C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Stephen J Hoffman director, officer: Chief Executive Officer C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301
Novartis Bioventures Ltd 10 percent owner C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
Ag Novartis 10 percent owner LICHTSTRASSE 35, BASEL V8 CH 4056

Aerpio Pharmaceuticals (Aerpio Pharmaceuticals) Headlines

From GuruFocus